Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2015-11-03
|
BI 1482694 (HM61713) |
T790M mutation-positive non-small cell lung cancer (NSCLC), whose tumours stopped responding to currently available epidermal growth factor receptor (EGFR) directed therapies |
2 |
Boehringer Ingelheim (Germany) |
Cancer - Oncology |
2015-11-03
|
atesidorsen (COR-004 -ATL1103 - 2'-O-(2-methoxyethyl) phosphorothioate antisense oligonucleotide targeting the growth hormone receptor) |
acromegaly |
2 |
Strongbridge Biopharma (Ireland) previously known as Cortendo (Sweden) |
Rare diseases - Hormonal diseases - Endocrine diseases |
2015-11-03
|
evofosfamide (TH-302) and immune checkpoint inhibitors |
|
preclinical |
Threshold Pharmaceuticals (USA - CA) |
Cancer - Oncology |
2015-11-02
|
NVP015 - Complex I Deficiency discovery program including succinate prodrug candidates |
mitochondrial disorders associated with complex I deficiency such as Leigh Syndrome |
preclinical |
Neurovive Pharmaceutical (Sweden) |
Rare diseases - Neurodegenerative diseases |
2015-11-02
|
tissue engineered replacement trachea |
severe structural airway disease (SSAD) |
1 |
Videregen (UK) |
Respiratory diseases - Regenerative medicine |
2015-11-02
|
VSN16R |
spasticity caused by multiple sclerosis |
2 |
Canbex Therapeutics (UK) |
Neurodegenerative diseases |
2015-11-02
|
NI-0101 ( anti-TLR4 ( toll-like receptor-4) monoclonal antibody) |
rheumatoid arthritis |
2 |
NovImmune (Switzerland) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2015-11-02
|
Keytruda® (pembrolizumab) |
colorectal carcinoma |
3 |
Merck&Co (USA - NJ) |
Cancer - Oncology |
2015-11-02
|
afatinib |
non-small cell lung cancer (NSCLC) |
2 |
Boehringer Ingelheim (Germany) |
Cancer - Oncology |
2015-10-31
|
GZ402668 |
progressive multiple sclerosis |
1 |
Genzyme (USA - MA), a Sanofi company (France) |
Autoimmune diseases - Neurodegenerative diseases |
2015-10-29
|
GTL001 (ProCervix®) |
treatment of adult women already infected with human papillomavirus (HPV) genotype 16 or 18 |
1 |
Genticel (France) |
Cancer - Oncology - Infectious diseases |
2015-10-29
|
ALKS 8700 (monomethyl fumarate) |
multiple sclerosis |
1 |
Alkermes (Ireland) |
Neurodegenerative diseases |
2015-10-29
|
crisaborole topical ointment (AN2728) |
mild-to-moderate atopic dermatitis |
3 |
Anacor Pharmaceuticals (US - CA) |
Dermatological diseases - Inflammatory diseases |
2015-10-29
|
AZP-531 (unacylated ghrelin analog) |
type 2 diabete, Prader-Willi syndrome |
1b |
Alize Pharma (France) |
Metabolic diseases |
2015-10-29
|
PBI-4050 - 3-pentylbenzenacetic acid sodium salt |
|
2 |
ProMetic Life Sciences (Canada) |
Metabolic diseases |
2015-10-29
|
denintuzumab mafodotin (SGN-CD19A) in combination with the second-line salvage regimen of rituximab (Rituxan®), ifosfamide, carboplatin and etoposide (RICE) |
relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or Grade 3b follicular lymphoma |
2 |
Seattle Genetics (USA - WA) |
Cancer - Oncology |
2015-10-29
|
rivipansel (GMI-1070) |
|
1 |
GlycoMimetics (USA - Md) |
Cancer - Oncology |
2015-10-29
|
SAR438335 |
diabetes |
1 |
Sanofi (France) |
Metabolic diseases |
2015-10-28
|
sNN0031 |
Parkinson’s disease |
2 |
Newron Pharmaceuticals (Italy) |
Neurodegenerative diseases |
2015-10-28
|
sNN0029 |
amyotrophic lateral sclerosis |
2 |
Newron Pharmaceuticals (Italy) |
Neurodegenerative diseases - Rare diseases |